Dechra Pharmaceuticals (LON:DPH) Share Price Crosses Above 200-Day Moving Average of $3,747.35

Dechra Pharmaceuticals PLC (LON:DPH – Get Rating)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 3,747.35 ($45.92) and traded as high as GBX 3,844 ($47.10). Dechra Pharmaceuticals shares last traded at GBX 3,578 ($43.84), with a volume of 213,969 shares.

Analysts Set New Price Targets

Separately, Royal Bank of Canada raised shares of Dechra Pharmaceuticals to an “outperform” rating and dropped their target price for the stock from GBX 5,300 ($64.94) to GBX 4,200 ($51.46) in a report on Tuesday, July 5th.

Dechra Pharmaceuticals Price Performance

The firm’s 50-day moving average price is GBX 3,524.96 and its 200-day moving average price is GBX 3,747.35. The company has a current ratio of 2.91, a quick ratio of 1.73 and a debt-to-equity ratio of 49.57. The stock has a market capitalization of £3.88 billion and a PE ratio of 5,340.30.

About Dechra Pharmaceuticals

(Get Rating)

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.

Read More

• MarketBeat: Week in Review 8/1 – 8/5
• How to Use High Beta Stocks to Maximize Your Investing Profits
• Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
• Why Apple Could Be At All-Time Highs By Year End
• Beyond Meat Is Not Beyond Hope, And It’s Cheap

Want More Great Investing Ideas?